Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis
American Journal of Ophthalmology Sep 09, 2017
Sepah YJ, et al. - A randomized, controlled, multicenter clinical trial is carried out to report the primary end-point analyses of the safety and effectiveness of two different doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with non-infectious intermediate, posterior or pan-uveitis. Based on these outcomes, repeated IV administrations of TCZ are well tolerated. TCZ (both 4 and 8 mg/kg) is successful in improving visual acuity (VA) and decreasing VH and central macular thickness (CMT) in eyes with non-infectious intermediate, posterior and pan-uveitis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries